Sage Therapeutics Inc Quick Ratio (SAGE) starting from the second quarter 2025 to second quarter 2024, Financial Strength Trends, Rankings, Financial Ratios - CSIMarket
CSIMarket Company Name, Ticker, Competitors, else..
 


• Quick Ratio
• Working Capital
• LT Debt to Equity
• Debt to Equity
• Leverage Ratio
• Tangible Leverage
• Interest Coverage
• Debt Coverage
• Work. Cap. Per Revenue
Sage Therapeutics Inc   (NASDAQ: SAGE)

Sage Therapeutics Inc 's Quick Ratio

SAGE's quarterly Quick Ratio and Cash & cash equivalent, Current Liabilities growth


Regardless of the sequential decrease in Current Liabilities, during the second quarter 2025, Quick Ratio deteriorated to 8.19 below Sage Therapeutics Inc 's average Quick Ratio.

Within Major Pharmaceutical Preparations industry 102 other companies have achieved higher Quick Ratio than Sage Therapeutics Inc in second quarter 2025. While Quick Ratio total ranking has improved so far during the Q2 2025 to 325, from total ranking in the first quarter 2025 at 350.

Explain Quick Ratio?
How much Cash & cash equivalents SAGE´s has?
What are SAGE´s Current Liabilities?



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

SAGE Quick Ratio (Jun 30 2025)
Q2		 (Mar 31 2025)
Q1		 (Dec 31 2024)
Q4		 (Sep 30 2024)
Q3		 (Jun 30 2024)
Q2
Y / Y Current Liabilities Change -33.99 % -14.9 % -7.69 % -52.07 % -30.14 %
Y / Y Cash & cash equivalent Change -43.6 % -41 % -33.15 % -34.88 % -35.36 %
Quick Ratio MRQ 8.19 8.51 7.04 9.44 9.58
SAGE's Total Ranking # 325 # 350 # 96 # 268 # 307
Seq. Current Liabilities Change -10.32 % -30.49 % 18.56 % -10.68 % 15.62 %
Seq. Cash & cash equivalent Change -13.75 % -15.97 % -11.58 % -11.98 % -9.78 %



Quick Ratio second quarter 2025 Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 103
Healthcare Sector # 165
Overall Market # 325


Quick Ratio Statistics
High Average Low
125.86 22.67 4.88
(Mar 31 2013)   (Sep 30 2017)




Financial Statements
Sage Therapeutics Inc 's Current Liabilities $ 45 Millions Visit SAGE's Balance sheet
Sage Therapeutics Inc 's Cash & cash equivalent $ 366 Millions Visit SAGE's Balance sheet
Source of SAGE's Sales Visit SAGE's Sales by Geography


Cumulative Sage Therapeutics Inc 's Quick Ratio

SAGE's Quick Ratio for the trailling 12 Months

SAGE Quick Ratio

 (Jun 30 2025)
12 Months		 (Mar 31 2025)
12 Months		 (Dec 31 2024)
12 Months		 (Sep 30 2024)
12 Months		 (Jun 30 2024)
12 Months
Y / Y Current Liabilities TTM Growth -31.33 % -30.5 % -32.97 % -35.07 % -13.33 %
Y / Y Cash & cash equivalent TTM Growth -37.79 % -35.94 % -35.12 % -37.13 % -37.54 %
Quick Ratio TTM 8.23 8.61 9.46 10.19 9.09
Total Ranking TTM # 320 # 2830 # 2111 # 2379 # 2914
Seq. Current Liabilities TTM Growth -9.22 % -3.38 % -2.26 % -19.9 % -8.13 %
Seq. Cash & cash equivalent TTM Growth -13.16 % -12.06 % -9.29 % -10.2 % -10.58 %

Quick ratio ranking by company, industry and sector >> Back to SAGE Financial Strength Comparisons >> Go to Compare SAGE Quick Ratio to its Competitors

On the trailing twelve months basis In spite of the year on year decrease in SAGE's Current Liabilities to $44.64 millions, cumulative Quick Ratio to 8.23 below the SAGE average Quick Ratio.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Major Pharmaceutical Preparations industry 13 other companies have achieved higher Quick Ratio than Sage Therapeutics Inc . While Quick Ratio overall ranking has improved so far to 320, from total ranking during the twelve months ending first quarter 2025 at 2830.

Explain Quick Ratio?
How much Cash & cash equivalents SAGE´s has?
What are SAGE´s Current Liabilities?

TTM Quick Ratio Company Ranking
Within: No.
Within the Major Pharmaceutical Preparations Industry # 14
Healthcare Sector # 43
Within the Market # 320


trailing twelve months Quick Ratio Statistics
High Average Low
28.06 14.2 2.29
(Sep 30 2021)   (March 31, 2014)




Companies with similar Quick Ratio in the quarter ending Jun 30 2025, within Major Pharmaceutical Preparations Industry Quick RatioJun 30 2025 MRQ Cash & cash equivalentJun 30 2025 MRQ Current Liabilities
Rapport Therapeutics Inc   21.92 $ 260.447  Millions$ 11.879  Millions
Keros Therapeutics Inc   21.88 $ 690.215  Millions$ 31.552  Millions
Newamsterdam Pharma Company N v   21.63 $ 739.162  Millions$ 34.175  Millions
Septerna Inc   21.59 $ 326.561  Millions$ 15.127  Millions
Tyra Biosciences Inc   21.52 $ 296.271  Millions$ 13.770  Millions
Prothena Corporation Public Limited Company  21.47 $ 371.435  Millions$ 17.298  Millions
Novabridge Biosciences  21.38 $ 23.300  Millions$ 1.090  Millions
Whitehawk Therapeutics Inc   20.24 $ 177.200  Millions$ 8.756  Millions
Mbx Biosciences Inc   19.13 $ 224.906  Millions$ 11.756  Millions
Stoke Therapeutics Inc   18.96 $ 247.708  Millions$ 13.062  Millions
Atea Pharmaceuticals Inc   18.87 $ 379.713  Millions$ 20.119  Millions
Context Therapeutics Inc   18.81 $ 83.517  Millions$ 4.441  Millions
Edesa Biotech Inc   18.43 $ 12.400  Millions$ 0.673  Millions
Ventyx Biosciences Inc   18.22 $ 208.959  Millions$ 11.469  Millions
Cervomed Inc   18.17 $ 33.531  Millions$ 1.846  Millions
Alto Neuroscience Inc   18.16 $ 147.585  Millions$ 8.129  Millions
Neurogene Inc   17.78 $ 274.519  Millions$ 15.440  Millions
Agios Pharmaceuticals Inc   17.78 $ 938.937  Millions$ 52.821  Millions
Sagimet Biosciences inc   17.68 $ 125.407  Millions$ 7.095  Millions
Annovis Bio Inc   17.58 $ 17.130  Millions$ 0.974  Millions
Crinetics Pharmaceuticals Inc   17.49 $ 1,196.360  Millions$ 68.396  Millions
Igm Biosciences Inc   17.21 $ 104.306  Millions$ 6.060  Millions
Synlogic Inc   17.08 $ 17.027  Millions$ 0.997  Millions
Vera Therapeutics Inc   17.03 $ 556.827  Millions$ 32.699  Millions
Adc Therapeutics Sa  16.95 $ 264.560  Millions$ 15.612  Millions
Dyne Therapeutics Inc   16.49 $ 683.925  Millions$ 41.472  Millions
Mereo Biopharma Group Plc  16.00 $ 77.417  Millions$ 4.838  Millions
Oric Pharmaceuticals Inc   15.65 $ 282.513  Millions$ 18.050  Millions
Moonlake Immunotherapeutics  15.54 $ 425.083  Millions$ 27.361  Millions
Nkarta Inc   15.31 $ 289.687  Millions$ 18.927  Millions

Date modified: 2026-09-18T13:11:06+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.